直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Successor-In-Interest Can Challenge Decisions by the Board and Assert Their Interests

February 19, 2021

Authored and Edited by Melissa C Santos, Ph.D.; Esther H. Lim; Christina Ji-Hye Yang; Elizabeth D. Ferrill

In Mojave Desert Holdings, LLC, v Crocs, Inc., No. 2020-1167 (Fed. Cir. Feb. 11, 2021), the Federal Circuit held that a successor-in-interest is a real party-in-interest to an inter partes reexamination.

Crocs sued U.S.A. Dawgs for infringement of U.S. Patent No. D517,789. U.S.A. Dawgs filed a third-party request for inter partes reexamination of the ’789 patent. U.S.A. Dawgs then filed for bankruptcy and sold its assets to Dawgs Holdings, LLC, including all “assets, properties and rights of every kind and nature.” Dawgs Holdings then assigned all rights to Mojave. The Board ultimately upheld the patent and denied Mojave’s petition to change the real party-in-interest. Mojave appealed.

The Federal Circuit held that because all rights had been assigned, including its interest in the inter partes reexamination, Mojave was the successor-in-interest. Accordingly, the Court held that the Board erred in denying Mojave’s petition to substitute for U.S.A. Dawgs as the real party-in-interest and that Mojave had standing to challenge to the ’789 patent. The Federal Circuit also held that U.S.A. Dawg retained the ability to file a protective notice of appeal, and doing so sufficed to confer jurisdiction on the Court. The Court then granted Mojave’s motion to substitute on appeal.

Tags

standing, rules and rules of practice, real parties in interest

For more information

  • Mojave Desert Holdings, LLC v. Crocs, Inc.

Related Practices

Design Rights

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Consumer Goods and Services

Consumer Products

Related Offices

Washington, DC

Contacts

Esther H. Lim
Partner and Chief Community Officer
Washington, DC
+1 202 408 4121
Email
Christina Ji-Hye Yang
Partner
Washington, DC
+1 202 408 4465
Email
Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP